News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NetRegulus NetRM Software Selected By Glucon To Support Next Phase Of Glucose Monitoring Device Clinical Trials


2/13/2006 10:30:49 AM

CENTENNIAL, Colo. and BOULDER, Colo., Feb. 13 /PRNewswire/ -- NetRegulus(R), Inc., an established provider of enterprise compliance software for regulated industries, today announced that Glucon Inc., the leading developer of glucose monitoring devices for the diabetes market, has selected the new NetRegulus NetRM(TM) Software as a Service (SaaS) Study solution to manage the next phase of the company's aggressive clinical trial schedule. The adoption of NetRegulus SaaS will provide Glucon with the tools to more quickly and effectively manage their clinical trial program. The software saves upfront investments in time and resources as well as the costs normally associated with the deployment of a leading edge clinical study solution.

"NetRegulus' experience and significant knowledge of regulated life sciences was a key factor in our decision process. The NetRegulus SaaS solution promises to help reduce time-to-market while simultaneously improving the ability to successfully manage critical data in preparation for successful FDA submissions," said Glucon CEO Dan Goldberger.

"We are proud to be supporting Glucon's entrance into this exciting emerging market," said Dave Siebert, President and CEO of NetRegulus. "We view Glucon as an innovator in the life sciences market and as such see this as an opportunity to directly contribute to the growth of this industry in general, and specifically in Colorado."

About Glucon

Glucon (www.glucon.com ) is developing a continuous, non-invasive, blood glucose (sugar) monitoring technology for home and clinical use. Glucon was founded in 2000 by two Israeli scientists, Company President Ron Nagar and V.P. of R&D, Dr. Benny Pesach. Glucon's technology enables blood glucose measurements to be accessed directly from inside the blood vessel. The company's flagship product, Aprise, is currently undergoing extensive clinical trials. Seed financing was provided by InnoMed Ventures, the life science fund of Jerusalem Global Ventures. Additional investors include Giza Venture Capital, Infinity Venture Capital Fund, Ascend Technology Ventures, Reslo Life Science and Suzuken. For additional information please contact Marjie Hadad, Media Liaison, Glucon, marjie@glucon.com or +972-54-536-5220.

About NetRegulus, Inc.

Located in Denver, CO, NetRegulus is a provider of web-based Enterprise Regulatory Management software that allows Life Science companies to effectively manage their clinical, study and quality data. Our products allow organizations to manage complex data requirements from clinical trials through regulated post market activities within a single integrated and modular system. Our products are developed to help Life Science companies meet ever increasing global regulatory requirements and to improve operational efficiencies, launch products to market faster and proactively identify potential product quality problems. http://www.netregulus.com

For additional information, contact: Joel Reed - Vice President of Marketing joel.reed@netregulus.com 888-707-6900

NetRegulus, Inc.

CONTACT: Joel Reed, Vice President of Marketing of NetRegulus, Inc.,+1-888-707-6900, joel.reed@netregulus.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES